Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Adrien Dixmier"'
Autor:
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, Christophe Raspaud, Jean-Bernard Auliac, Nicolas Benoit, Pierre Bombaron, Denis Moro-Sibilot, Clarisse Audigier-Valette, Bernard Asselain, Thomas Egenod, Audrey Rabeau, Jérôme Fayette, Myriam Locatelli Sanchez, Jean-Luc Labourey, Virginie Westeel, Pauline Lamoureux, François-Emery Cotte, Victoria Allan, Melinda Daumont, Juliette Dumanoir, Dorothée Reynaud, Christophe Yannick Calvet, Nicolas Ozan, Maurice Pérol
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and
Externí odkaz:
https://doaj.org/article/213acd05a7a34a719db64a6b6903acd4
Autor:
Christophe Gut-Gobert, Arnaud Cavaillès, Adrien Dixmier, Stéphanie Guillot, Stéphane Jouneau, Christophe Leroyer, Sylvain Marchand-Adam, David Marquette, Jean-Claude Meurice, Nicolas Desvigne, Hugues Morel, Christine Person-Tacnet, Chantal Raherison
Publikováno v:
European Respiratory Review, Vol 28, Iss 151 (2019)
The increasingly female face of chronic obstructive pulmonary disease (COPD) prevalence among women has equalled that of men since 2008, due in part to increased tobacco use among women worldwide and exposure to biomass fuels. This finding is support
Externí odkaz:
https://doaj.org/article/e16d09051ae3468698eb74fde18ea135
Autor:
Arnaud Cavaillès, Graziella Brinchault-Rabin, Adrien Dixmier, François Goupil, Christophe Gut-Gobert, Sylvain Marchand-Adam, Jean-Claude Meurice, Hugues Morel, Christine Person-Tacnet, Christophe Leroyer, Patrice Diot
Publikováno v:
European Respiratory Review, Vol 22, Iss 130, Pp 454-475 (2013)
By 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality. Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco smoking is a common risk factor for many comorbidities, including coronary
Externí odkaz:
https://doaj.org/article/c19ba4911d304b649bb34a1940eb678d
Autor:
Didier, Debieuvre, Charles, Dayen, Adrien, Dixmier, David, Pau, Anna, Sibley-Revelat, William, Greenwood, Samuel, Gally, Lionel, Falchero
Publikováno v:
Lung Cancer. 164:1-7
FRESC reanalyzed extensive-stage small-cell lung cancer (ES-SCLC) patient data from the French KBP-2010 cohort to describe the characteristics and therapeutic management of ES-SCLC and provide real-world estimates of survival.A target population of f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::964be8566074c048c54425b7e78c19ce
https://doi.org/10.1016/j.lungcan.2021.11.013
https://doi.org/10.1016/j.lungcan.2021.11.013
Autor:
D Waldenberger, John R. Penrod, Clarisse Audigier-Valette, Sylvia Gütz, Martin Sebastian, Adrien Dixmier, Christian Schumann, Khalid Lakhdari, Rosalyn A. Juergens, Didier Debieuvre, P. Bombaron, Nicolas Benoit, Jean-Bernard Auliac, Ariadna Juarez-Garcia, Catherine Labbé, Victoria Allan, Christophe Raspaud, Bernard Asselain, Dorothee Reynaud, Andreas Gröschel, Fabrice Barlesi, Maurice Pérol, Filippa Pettersson, Charles A. Butts, Denis Moro-Sibilot
Publikováno v:
Lung Cancer. 157:40-47
Objectives Immune checkpoint inhibitors have become the standard of care for metastatic non–small-cell lung cancer (NSCLC) progressing during or after platinum-based chemotherapy. Real-world clinical practice tends to represent more diverse patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d6bb6e2416028ec4bfcdabf66125207
https://doi.org/10.1016/j.lungcan.2021.04.022
https://doi.org/10.1016/j.lungcan.2021.04.022
Autor:
Bruno Coudert, Bénédicte Mastroianni, P. Foucher, Séverine Fraboulet, Adrien Dixmier, Julien Mazieres, Michel Vincent, Eric Dansin, Eric Pichon, M. Locatelli-Sanchez, Jacques Cadranel, Sébastien Couraud, N. Baize, Isabelle Monnet, Franck Morin, Catherine Dubos-Arvis, P. Missy, C. Fontaine-Delaruelle, Patrick Dumont, Denis Moro-Sibilot
Publikováno v:
Respiratory Medicine and Research
Respiratory Medicine and Research, Elsevier, 2020, 77, pp.58-66. ⟨10.1016/j.resmer.2020.01.003⟩
Respiratory Medicine and Research, Elsevier, 2020, 77, pp.58-66. ⟨10.1016/j.resmer.2020.01.003⟩
Background Lung cancer in women is on the rise, with a higher proportion occurring in lifelong never-smokers. Lung cancer in never-smokers (LCINS) exhibits a high frequency of driver oncogene alterations. In this study, we aimed to investigate whethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::185e5033e4087f3fe19b47a8d728a5c9
https://doi.org/10.1016/j.resmer.2020.01.003
https://doi.org/10.1016/j.resmer.2020.01.003
Autor:
Pauline Lamoureux, Denis Moro-Sibilot, Thomas Egenod, P. Bombaron, Melinda Daumont, Audrey Rabeau, Adrien Dixmier, Christophe Raspaud, Nicolas Benoit, Didier Debieuvre, N. Ozan, Juliette Dumanoir, Bernard Asselain, Virginie Westeel, C. Calvet, Clarisse Audigier-Valette, Dorothee Reynaud, Victoria Allan, Fabrice Barlesi, François-Emery Cotté, Maurice Pérol, Jean-Bernard Auliac, Jérôme Fayette, Jean-Luc Labourey, Myriam Locatelli Sanchez
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b3aa8e4cd6d1d9936466474b2b2ea83
https://pubmed.ncbi.nlm.nih.gov/33457089
https://pubmed.ncbi.nlm.nih.gov/33457089
Autor:
Victoria Allan, C. Raspaud, Fabrice Barlesi, Jean-Bernard Auliac, Maurice Pérol, J. Dumanoir, Adrien Dixmier, Dorothee Reynaud, Bernard Asselain, B. Nicolas, D. Moro-Sibilot, C. Calvet, Clarisse Audigier-Valette, P. Bombaron, Didier Debieuvre, F-E. Cotte
Publikováno v:
Annals of Oncology. 32:S1026
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::323b9cd30e9f0f998a4a9940e61e2d05
https://doi.org/10.1016/j.annonc.2021.08.1949
https://doi.org/10.1016/j.annonc.2021.08.1949
Autor:
Alexandra Langlais, Sylvestre Le Moulec, Julien Mazieres, Benjamin Besse, Charles Dayen, Adrien Dixmier, Gérard Zalcman, Olivier Molinier, Sandrine Hiret, Eric Pichon, Fabrice Barlesi, Catherine Becht, Olivier Raffy, Patrick Dumont, Alexis B. Cortot, Denis Moro-Sibilot, Claire Poulet, Patrick-Aldo Renault, Franck Morin, Clarisse Audigier-Valette, Damien Pouessel
Publikováno v:
SSRN Electronic Journal.
Purpose: Second-line chemotherapy regimens have demonstrated poor benefit after failure of platinum-based chemotherapy in advanced non-squamous non-small-cell-lung cancer (nsNSCLC). Methods: In this multicentre, open-label phase 3 trial, patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e22ea831a0dd222feabb15d23f1a98cd
https://doi.org/10.2139/ssrn.3410910
https://doi.org/10.2139/ssrn.3410910
Autor:
Adrien Dixmier, Denis Moro-Sibilot, Andreas Gröschel, Fabrice Barlesi, Sylvia Gutz, Maurice Pérol, Christian Schumann, John R. Penrod, Didier Debieuvre, Charles A. Butts, Dorothee Reynaud, D Waldenberger, Khalid Lakhdari, Filippa Pettersson, Martin Sebastian, Catherine Labbé, Clarisse Audigier-Valette, Victoria Allan, Rosalyn A. Juergens, Ariadna Juarez-Garcia
Publikováno v:
Journal of Clinical Oncology. 38:e21714-e21714
e21714 Background: Data from clinical studies demonstrate a long-term survival benefit of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC) patients with overall survival (OS) at two-years of 27%, however real-world data are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12df7eb578dcfe13c385d6c87c60beb0
https://doi.org/10.1200/jco.2020.38.15_suppl.e21714
https://doi.org/10.1200/jco.2020.38.15_suppl.e21714